Tesamorelin vs Ipamorelin: GHRH Analog vs GHRP Comparison

Tesamorelin vs Ipamorelin: GHRH Analog vs GHRP Comparison Tesamorelin vs Ipamorelin compared: FDA-approved GHRH analog vs research GHRP, mechanisms, dosing, evidence grades, side effects, and cost. Tesamorelin is a synthetic GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy, stimulating the pituitary directly for GH release with the strongest clinical trial backing in this category. Ipamorelin is a research-only selective GHRP that produces clean, pulsatile GH release through a separate receptor pathway with minimal cortisol, prolactin, or appetite effects. Because they act on different receptors, the two are commonly researched together rather than as substitutes for each other. Class GHRH analog GHRP (selective ghrelin/GHS-R agonist) Mechanism Synthetic GHRH analog; pituitary GH release with physiological feedback regulation Selective GHSR agonist; pulsatile GH release without raising cortisol, prolactin, or ACTH Evidence Grade A B Route Subcutaneous injection Typical Dose 2 mg once daily 100-300 mcg, 1-3x daily Half-Life ~26-38 minutes ~2 hours FDA Status Approved (Egrifta, HIV-associated lipodystrophy) Not approved; research compound Reported Outcomes Visceral fat reduction (HIV lipodystrophy trials), improved waist circumference, cognitive improvement (pilot data) Selective GH release, improved body composition, enhanced sleep quality Reported Side Effects Injection site reactions, arthralgia/myalgia, peripheral edema Mild water retention, transient head rush post-injection, mild hunger increase Storage Refrigerate 2-8°C Refrigerate 2-8°C once reconstituted; use within 28 days Cost (research grade) $400-800 brand; $100-200 compounded $45-90/month FDA-approved with published human clinical trial data Direct GHRH-receptor mechanism, closest to natural GH signaling Once-daily dosing Strongest evidence base for visceral fat reduction Preserves physiological negative-feedback regulation Short half-life requires consistent daily timing Higher cost than most research GHRPs Injection site reactions more frequently reported than with ipamorelin Approval is specific to HIV-associated lipodystrophy, not general GH optimization Cleanest side-effect profile among common GHRPs No significant cortisol, prolactin, or ACTH elevation Minimal appetite stimulation Lower cost per month than tesamorelin Commonly stacked with a GHRH analog for combined effect Not FDA-approved; research-use only Requires 1-3 daily subcutaneous injections Acts on a separate receptor from GHRH analogs, so it doesn't replace tesamorelin's mechanism Reconstitution and cold-chain storage required Choose Tesamorelin if: Regulatory status and published clinical evidence matter for your research context, or the focus is specifically visceral fat reduction. It has the strongest trial data of any compound in this category and is the only one with FDA approval. Choose Ipamorelin if: The goal is a clean, selective GH pulse with minimal off-target hormone effects, and injection frequency (1-3x daily) is acceptable. It's also the standard choice to pair with a GHRH analog. Key trade-off: Tesamorelin and ipamorelin act on different receptors (GHRH vs ghrelin/GHS-R), so this isn't strictly an either/or choice the way MK-677 vs Ipamorelin is. Many research protocols use tesamorelin's GHRH-pathway stimulation alongside ipamorelin's GHRP-pathway pulse rather than choosing one over the other. They work differently and aren't strict substitutes. Tesamorelin is a GHRH analog with FDA approval (Egrifta) and published human trial data on visceral fat reduction; it stimulates the pituitary directly and has a short 26-38 minute half-life dosed once daily. Ipamorelin is a GHRP that stimulates a separate receptor pathway (ghrelin/GHS-R) for cleaner, more selective pulsatile GH release with minimal cortisol or prolactin elevation. Tesamorelin has stronger clinical backing; ipamorelin has a milder side-effect profile and is frequently paired with a GHRH analog rather than used as a replacement for one. Yes, and this is a common research stack. Because tesamorelin acts on the GHRH receptor and ipamorelin acts on the separate ghrelin/GHS receptor, the two pathways are considered complementary rather than redundant — similar in principle to a CJC-1295 + ipamorelin stack. Combining a GHRH analog with a GHRP is generally reported to produce a larger GH pulse than either compound alone. Yes — tesamorelin is FDA-approved under the brand name Egrifta for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy, one of the few peptides in this category with that regulatory status. Ipamorelin is not FDA-approved and remains a research-use compound. Verified Research Suppliers Research-grade peptides are available from verified suppliers listed on our Vendor Comparison page. All listed vendors meet cGMP certification and third-party testing standards. Related Tools & Resources